Rhythm Pharmaceuticals Presents Data from its Long-term Exte

-- Patients with hypothalamic obesity achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal...

Related Keywords

Boston , Massachusetts , United States , Dallas , Texas , United Kingdom , Germany , Columbia University , New York , Canada , Andrea Haqq , David Connolly , Wendyk Chung , David Meeker , Adam Daley , Jack Yanovski , Martin Wabitsch , Jeremy Pomeroy , Christianl Roth , Department Of Pediatrics , National Institutes Of Health , European Commission , Us National Institutes Of Health , European Union , Corporate Communications , Rhythm Pharmaceuticals , Nasdaq , Rhythm Pharmaceuticals Inc , University Of Alberta , Medicines Healthcare Products Regulatory Agency , University Of Ulm , Division Of Molecular Genetics , Obesity Society Annual Meeting At Obesityweek , Human Development , Drug Administration , Marshfield Clinic Research Institute , Division Of Pediatric Endocrinology , Seattle Children Research Institute , World Health Organization , Berry Company Public Relations , Exchange Commission , Obesity Society , Annual Meeting , Chief Executive Officer , Obesity Data , Patients With Hypothalamic Obesity Treated , Seattle Children , Research Institute , Bardet Biedl Syndrome Data , Three Years , Year Setmelanotide Weight Outcomes , Bardet Biedl Syndrome , Eunice Kennedy Shriver National Institute , Child Health , National Institutes , Molecular Genetics , Metabolic Syndrome Risk , Adolescent Medicine , Diabetes Mellitus Outcomes , Clinical Registry Investigating , Pediatric Endocrinology , Investor Relations , Healthcare Products Regulatory Agency , Blood Pressure Monitoring , Penile Erection , Prescribing Information , Important Safety , Private Securities Litigation Reform Act , Quarterly Report , Company Public Relations , Markets ,